Oncolytic HSV1716

Drug Overview

Oncolytic HSV1716 (brand name Seprehvir) is an investigational, genetically modified oncolytic virus derived from the Herpes Simplex Virus type 1 (HSV-1). It is specifically engineered to selectively infect, replicate within, and destroy cancer cells while leaving healthy, non-dividing cells (such as normal neurons) unharmed.

In the clinical landscape of March 2026, HSV1716 is recognized as a pioneer in “Immunovirotherapy.” Developed by Virttu Biologics (now part of Sorrento Therapeutics), this virus is a “first-generation” oncolytic agent that has been extensively studied in both adults and children. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, HSV1716 exploits the unique “broken” antiviral pathways found in tumor cells. It acts as a biological weapon that physically ruptures the tumor from the inside and simultaneously “unmasks” the cancer to the patient’s own immune system.

• Generic Name: Oncolytic HSV1716.
• Brand Name: Seprehvir.
• Drug Class: Oncolytic Virotherapy; HSV-1 based Immunotherapy.
• Mechanism: Selective viral replication in tumor cells leading to oncolysis and induction of an anti-tumor immune response.
• Route of Administration: Intratumoral (direct injection), Intravenous (IV), or Intraperitoneal (IP).
• FDA Approval Status: Investigational. As of March 2026, HSV1716 is not FDA-approved. It has been granted Orphan Drug Designation for several indications, including glioblastoma and mesothelioma, and is currently being evaluated in Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

HSV1716 works through a “search-and-destroy” mission that leverages the natural biology of the herpes virus.

1. The “Safety Switch” (ICP34.5 Deletion)

The core of HSV1716’s technology is the deletion of both copies of the ICP34.5 gene.

• In Healthy Cells: Normal cells use this gene to signal the immune system to stop protein production when a virus is detected, effectively “starving” the virus. Without this gene, HSV1716 cannot replicate in healthy tissue.
• In Cancer Cells: Tumors often “turn off” these antiviral defense pathways so they can grow unchecked. HSV1716 takes advantage of this “broken” defense, allowing it to replicate freely within the tumor.

2. Direct Oncolysis (Cell Bursting)

Once inside the tumor cell, HSV1716 turns the cell into a “virus factory.”

• Viral Proliferation: The virus makes thousands of copies of itself.
• Cell Rupture: Eventually, the cancer cell becomes so bloated with viral particles that it bursts (lyses). This physically destroys the tumor cell.

3. The “In Situ” Vaccine Effect

When the cancer cell ruptures, it releases more than just viruses.

• Antigen Release: Hidden tumor-specific proteins (antigens) and “danger signals” are released into the surrounding tissue.
• Immune Recruitment: These signals act like an alarm for the patient’s immune system. T-cells and Natural Killer (NK) cells are drawn to the site, where they learn to recognize and attack the cancer. This can lead to the destruction of metastatic tumors that were never even touched by the virus—a phenomenon known as the “Abscopal Effect.”

Clinical Indications and Research Status (2026)

HSV1716 has been evaluated in over 100 patients across various aggressive cancer types:

• Glioblastoma Multiforme (GBM): Studied in both adults and children. Recent 2025 data showed that direct injection into the brain tumor was safe and led to long-term survival in a subset of patients.
• Malignant Mesothelioma: Evaluated via intrapetal (IP) administration to target tumors lining the chest or abdomen.
• Pediatric Solid Tumors: Investigated for children with relapsed neuroblastoma, osteosarcoma, and rhabdomyosarcoma.
• Melanoma and Squamous Cell Carcinoma: Studied via direct injection into skin lesions to trigger a systemic immune response.

Dosage and Administration Protocols

As an investigational agent, the administration of HSV1716 is strictly managed within clinical trials (such as the SEPREHVIR-101 study).

Clinical Efficacy and Research Results (2024–2026)

Recent trials have focused on combining HSV1716 with other modern therapies:

• Synergy with Checkpoint Inhibitors: Research in late 2025 showed that “priming” a tumor with HSV1716 makes it much more sensitive to immunotherapies like pembrolizumab or nivolumab, turning “cold” tumors “hot.”
• Brain Tumor Survival: A 2024 follow-up study of pediatric glioblastoma patients showed that some children remained in remission for over 3 years after receiving the virus—a significant achievement in this high-risk population.
• Safety Profile: Across all trials, HSV1716 has shown a remarkable safety record, with no instances of “herpes infection” or serious systemic toxicity reported in over two decades of study.

Safety Profile and Side Effects

Because HSV1716 is highly targeted, it does not cause the typical “chemo side effects” like hair loss or severe nausea.

Common Side Effects (>40%):

• Flu-like Symptoms: Fever, chills, muscle aches, and fatigue. These are most common during the first 24–48 hours after treatment as the immune system reacts.
• Local Inflammation: Redness or swelling at the site of the injection.
• Headache: Especially when administered into the brain or spinal fluid.

Serious Risks:

• Brain Swelling (Edema): In brain tumor cases, the immune system’s reaction can cause temporary swelling, which may require steroid treatment (dexamethasone).
• Viral Shedding: There was historical concern about the virus being “shed” in saliva or urine; however, clinical data in 2025 confirmed that shedding is negligible and poses no risk to family members.
• Infection: Rare risk of infection at the injection site.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, HSV1716 is being used to study “Cancer Stem Cell Targeting.” Researchers are investigating how the virus can find and destroy “quiescent” (sleeping) cancer stem cells that are normally resistant to chemotherapy. In 2026, there is also intense focus on “Armed Viruses.” Scientists are developing a newer version of HSV1716 that carries a “payload” (like a gene for a cytokine) to further boost the immune response once it gets inside the tumor.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Immune Status Check: Patients must have a functional immune system to benefit from the “vaccine effect” of the virus.
• Baseline Imaging: High-resolution MRI or CT scans are needed to map the tumor for injection.

“Do’s and Don’ts” List:

• DO expect “flu-like” symptoms for a day or two after your treatment; rest and hydration are key.
• DO report any new “weakness” or “extreme sleepiness” immediately if you are being treated for a brain tumor.
• DON’T worry about “catching” herpes from this treatment; the virus is too genetically altered to cause cold sores or shingles.
• DON’T take high-dose steroids unless directed, as they can “dampen” the immune system and prevent the virus from working.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Oncolytic HSV1716 (Seprehvir) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.